制备T淋巴瘤TCR V β核酸疫苗。方法：= 利用RT-PCR方法扩增出人T淋巴瘤细胞Jurkat 的TCR V β基因片段，并将其重组入真核表达载体pcDNA3。用重组表达载体转染SP2/0细胞，在mRNA水平上检测其表达。再用pcDNA3和重组载体分别免疫BALB/c小鼠，收集抗血清，用免疫组化技术检测抗体产生情况。结果： 扩增出TCR V β的基因片段，测序结果证实其序列与已发表的一致。并构建出重组表达载体pcDNA3-TCR V β。该质粒转染到SP2/0细胞，可在mRNA水平上检测到其表达。在用pcDNA3-TCR V β免疫的小鼠抗血清中检测到抗Jurkat细胞TCR V β的抗体。免疫组化结果表明，该血清不与表达TCR γδ的人T淋巴瘤细胞发生反应，而与转染该基因的SP2/0细胞产生强阳性反应。正常小鼠血清与pcDNA3免疫的小鼠血清与Jurkat细胞不产生显色反应。结论：所制备的T淋巴瘤TCR Vβ核酸疫苗能有效地诱导机体产生体液免疫反应。

To construct TCR V β nucleic acid vaccine. Methods: A fragment of TCR V β gene was amplified by RT-PCR from a human T lymphoma cell line, Jurkat, and cloned into eukaryotic expression plasmid pcDNA3 by gene recombination. After sequencing, the recombinant plasmid was transfected into SP2/0 cells and its expression was detected on mRNA level. BALB/c mice were immunized with pcDNA3 and the recombinant plasmid by intramuscular routes. Antiserum was collected and detected by immunocytochemistry method. Results: A fragment of TCR V β gene from Jurkat cells was obtained and proved to be identical to published sequence. A recombinant plasmid pcDNA3-TCR V β was constructed. Its expression was detectable on mRNA level after being transfected into SP2/0 cells. Antiserum from mice immunized with pcDNA3-TCR V β reacted strongly with Jurkat cells and SP2/0 cells transfected by pcDNA3-TCR V β, while shows no reaction on CEM cells expressing TCRγδ and SP2/0 cells. Antisera from normal mice and mice immunized with pcDNA3 were both negative on Jurkat cells. The results of immunocytochemistry indicated that BALB/c mice immunized with pcDNA3-TCR V β produced specific antibody to Jurkat TCR V β. Conclusion: The TCR V β nucleic acid vaccine we constructed can induce humoral immunity.